Hormone boost may sharpen prostate cancer scans

NCT ID NCT07025369

Recruiting now Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a short course of hormone therapy (relugolix) can make PSMA PET/CT scans better at finding prostate cancer that has spread to lymph nodes. About 30 men with high-risk prostate cancer will get the hormone drug for 5, 10, or 15 days before their scan. The goal is to see if the treatment increases the cancer cells' brightness on the scan, helping doctors detect smaller areas of disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA STAGE IIC PROSTATE CANCER AJCC V8 STAGE III PROSTATE CANCER AJCC V8 STAGE IV PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.